Bioventus (BVS) EBT (2020 - 2026)

Bioventus (BVS) has reported EBT for 7 consecutive years, with $15.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 48.43% year-over-year to $15.3 million; the trailing twelve-month figure through Jun 2026 stood at $38.6 million (up 2339.27% YoY), and the FY2025 full-year result was $25.7 million, up 149.12% from the prior year.
• EBT grew to $15.3 million in Q2 2026 per BVS's latest filing, from $4.5 million in the prior quarter.
• Across five years, EBT topped out at $15.3 million in Q2 2026 and bottomed at -$130.6 million in Q4 2022.
• Historically, EBT has averaged -$17.6 million across 5 years, with a median of -$5.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: EBT sank 4043.38% in 2022, then soared 26784.91% in 2025.
• Over 5 years, EBT stood at -$32.4 million in 2022, then jumped by 74.09% to -$8.4 million in 2023, then soared by 99.37% to -$53000.0 in 2024, then jumped by 26784.91% to $14.1 million in 2025, then gained by 8.24% to $15.3 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $15.3 million, $4.5 million, and $14.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.